AAAAAA
Results: 1-25/80
Authors:
NEMUNAITIS J
POOLE C
PRIMROSE J
ROSEMURGY A
MALFETANO J
BROWN P
BERRINGTON A
CORNISH A
LYNCH K
RASMUSSEN H
KERR D
COX D
MILLAR A
Citation: J. Nemunaitis et al., COMBINED ANALYSIS OF STUDIES OF THE EFFECTS OF THE MATRIX METALLOPROTEINASE INHIBITOR MARIMASTAT ON SERUM TUMOR-MARKERS IN ADVANCED CANCER - SELECTION OF A BIOLOGICALLY-ACTIVE AND TOLERABLE DOSE FOR LONGER-TERM STUDIES, Clinical cancer research, 4(5), 1998, pp. 1101-1109
Authors:
NEMUNAITIS J
POOLE C
PRIMROSE J
ROSEMURGY A
MALFETANO J
BROWN P
BERRINGTON A
CORNISH A
LYNCH K
RASMUSSEN H
KERR D
COX D
MILLAR A
Citation: J. Nemunaitis et al., COMBINED ANALYSIS OF STUDIES OF THE EFFECTS OF THE MATRIX METALLOPROTEINASE INHIBITOR MARIMASTAT ON SERUM TUMOR-MARKERS IN ADVANCED CANCER - SELECTION OF A BIOLOGICALLY-ACTIVE AND TOLERABLE DOSE FOR LONGER-TERM STUDIES, Clinical cancer research, 4(5), 1998, pp. 1101-1109
Authors:
NEMUNAITIS J
Citation: J. Nemunaitis, USE OF MACROPHAGE-COLONY-STIMULATING FACTOR IN THE TREATMENT OF FUNGAL-INFECTIONS, Clinical infectious diseases, 26(6), 1998, pp. 1279-1281
Authors:
NEMUNAITIS J
BOHART C
FONG T
MEYER W
EDELMAN G
PAULSON RS
ORR D
JAIN V
OBRIEN J
KUHN J
KOWAL KJ
BURKEHOLDER S
BRUCE J
OGNOSKIE N
WYNNE D
MARTINEAU D
ANDO D
Citation: J. Nemunaitis et al., PHASE-I TRIAL OF RETROVIRAL VECTOR-MEDIATED INTERFERON (IFN)-GAMMA GENE-TRANSFER INTO AUTOLOGOUS TUMOR-CELLS IN PATIENTS WITH METASTATIC MELANOMA, Cancer gene therapy, 5(5), 1998, pp. 292-300
Authors:
KAYE S
NEMUNAITIS J
GANLY I
POSNER M
VOKES E
KUHN J
HEISE C
MAACK C
KIRN D
Citation: S. Kaye et al., A PHASE-II TRIAL OF INTRATUMORAL INJECTION WITH AN E1B-DELETED ADENOVIRUS, ONYX-015, IN PATIENTS WITH RECURRENT, REFRACTORY HEAD AND NECK-CANCER, Annals of oncology, 9, 1998, pp. 61-61
Authors:
NEMUNAITIS J
BRUCE J
MONGIOVI D
WEINBERGER K
AZAD R
MONIA B
JOHNSTON J
GEARY R
KWOH J
DORR A
HOLMLUND J
Citation: J. Nemunaitis et al., PHASE-I TRIAL OF ISIS-2503, A 20-MER ANTISENSE PHOSPHOROTHIOATE OLIGONUCLEOTIDE AGAINST H-RAS, BY 14-DAY CONTINUOUS-INFUSION IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9, 1998, pp. 324-324
Authors:
KAYE S
NEMUNAITIS J
GANLY I
POSNER M
VOKES E
KUHN J
HEISE C
MAACK C
KIRN D
Citation: S. Kaye et al., A PHASE-II TRIAL OF INTRATUMORAL INJECTION WITH AN E1B-DELETED ADENOVIRUS, ONYX-015, IN PATIENTS WITH RECURRENT, REFRACTORY HEAD AND NECK-CANCER, Annals of oncology, 9, 1998, pp. 326-326
Authors:
MATEI C
NEMUNAITIS J
GRIEGO C
HOFF P
HANHAM A
CALLAHAN J
PAZDUR R
Citation: C. Matei et al., PHASE-I TRIAL OF BOF-A2 (EMITEFUR) PLUS LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED COLORECTAL-CANCER (CRC), Annals of oncology, 9, 1998, pp. 639-639
Authors:
GEYER C
NEMUNAITIS J
HOFF P
GRIEGO C
HANHAM A
CALLAHAN H
PAZDUR R
Citation: C. Geyer et al., PHASE-I TRIAL OF BOF-AS (EMITEFUR) - A NOVEL ORAL FLUORINATED PYRIMIDINE, Annals of oncology, 9, 1998, pp. 640-640
Authors:
MEROPOL NJ
WOOD DE
NEMUNAITIS J
PETRELLI NJ
LIPMAN BJ
AGOSTI JM
WHITMORE JB
Citation: Nj. Meropol et al., RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AS INFECTION PROPHYLAXIS IN ONCOLOGICSURGERY, Journal of clinical oncology, 16(3), 1998, pp. 1167-1173
Authors:
SINGH A
TONG A
OGNOSKIE N
MEYER W
NEMUNAITIS J
Citation: A. Singh et al., IMPROVED SURVIVAL IN PATIENTS WITH ADVANCED COLORECTAL-CARCINOMA FAILING 5-FLUOROURACIL WHO RECEIVED IRINOTECAN HYDROCHLORIDE AND HAVE HIGHINTRATUMOR C-FOS EXPRESSION, American journal of clinical oncology, 21(5), 1998, pp. 466-469
Authors:
NEMUNAITIS J
BUCKNER CD
DORSEY KS
WILLIS D
MEYER W
APPELBAUM F
Citation: J. Nemunaitis et al., RETROSPECTIVE ANALYSIS OF INFECTIOUS-DISEASE IN PATIENTS WHO RECEIVEDRECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR VERSUS PATIENTS NOT RECEIVING A CYTOKINE WHO UNDERWENT AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR TREATMENT OF LYMPHOID CANCER, American journal of clinical oncology, 21(4), 1998, pp. 341-346
Authors:
NEMUNAITIS J
COX J
MEYER W
COURTNEY A
HANSON T
GREENWEAVER C
AGOSTI J
Citation: J. Nemunaitis et al., COMPARISON OF NEUTROPHIL AND MONOCYTE FUNCTION BY MICROBICIDAL CELL-KILL ASSAY IN PATIENTS WITH CANCER RECEIVING GRANULOCYTE-COLONY-STIMULATING FACTOR, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, OR NO CYTOKINE AFTER CYTOTOXIC CHEMOTHERAPY - A PHASE-II TRIAL, American journal of clinical oncology, 21(3), 1998, pp. 308-312
Authors:
NEMUNAITIS J
KLEMOW S
TONG A
COURTNEY A
JOHNSTON W
MACK M
TAYLOR W
SOLANO M
STONE M
MALLAMS J
MUES G
Citation: J. Nemunaitis et al., PROGNOSTIC VALUE OF K-RAS MUTATIONS, RAS ONCOPROTEIN, AND C-ERB B-2 ONCOPROTEIN EXPRESSION IN ADENOCARCINOMA OF THE LUNG, American journal of clinical oncology, 21(2), 1998, pp. 155-160
Authors:
NEMUNAITIS J
MARTIN DE
WILLIS DL
FREED MI
LEVITT B
RICHARDS DA
COX JV
KIMMEL GT
HYMAN WJ
JORKASKY DK
Citation: J. Nemunaitis et al., SK-AND-F107647 - A SYNTHETIC HEMATOREGULATORY PEPTIDE IN PATIENTS WITH SOLID TUMOR MALIGNANCIES - A PHASE-I TRIAL, American journal of clinical oncology, 21(2), 1998, pp. 189-194
Authors:
DORR FA
SIKIC BI
NEMUNAITIS J
ECKHARDT G
YUEN AR
Citation: Fa. Dorr et al., ISIS 3521 CGP 64128A - ANTISENSE TO PROTEIN-KINASE-C/, European journal of cancer, 33, 1997, pp. 115-115
Authors:
MERRITT JA
CLAYMAN GL
SWISHER S
NEMUNAITIS J
ELNAGGAR A
GINSBERG L
LAWRENCE D
TIMMONS T
HENDERSON Y
FREDERICK M
CONNORS D
HUTCHISON A
BRUSO P
ROTH JA
SHULKIN A
WEILL D
WAIT J
Citation: Ja. Merritt et al., CLINICAL-PHASE-I EXPERIENCE WITH INGN-201 (AD-P53) IN NONSMALL CELL LUNG-CANCER AND HEAD AND NECK-CANCER, Cancer gene therapy, 4(6), 1997, pp. 1-1
Authors:
KIRN D
GANLEY I
NEMUNAITIS J
OTTO R
SOUTAR D
KUHN J
HEISE C
PROPST M
MAACK C
ECKHARDT G
KAYE S
VONHOFF D
Citation: D. Kirn et al., A PHASE-I CLINICAL-TRIAL WITH ONYX-015 (A SELECTIVELY REPLICATING ADENOVIRUS) ADMINISTERED BY INTRATUMORAL INJECTION IN PATIENTS WITH RECURRENT HEAD AND NECK-CARCINOMA, Cancer gene therapy, 4(6), 1997, pp. 5-5
Authors:
MERRITT JA
CLAYMAN G
SCHWISHER S
NEMUNAITIS J
ELNAGGAR A
TIMMONS T
LAWRENCE D
KEMP B
FREDERICK M
CONNORS D
BRUSO P
GOEPFERT H
HONG WK
ROTH JA
Citation: Ja. Merritt et al., CLINICAL GENE-THERAPY STRATEGIES - PHASE-I PHASE-II RESULTS WITH ADENOVIRAL P53 (INGN-201) GENE-TRANSFER IN ADVANCED HEAD AND NECK AND NON-SMALL-CELL LUNG CANCERS/, Cancer gene therapy, 4(5), 1997, pp. 330-330
Authors:
GORDON AN
STRINGER CA
MATTHEWS CM
WILLIS DI
NEMUNAITIS J
Citation: An. Gordon et al., PHASE-I DOSE-ESCALATION OF PACLITAXEL IN PATIENTS WITH ADVANCED OVARIAN-CANCER RECEIVING CISPLATIN - RAPID DEVELOPMENT OF NEUROTOXICITY IS DOSE-LIMITING, Journal of clinical oncology, 15(5), 1997, pp. 1965-1973
Authors:
COLLINS RH
SHPILBERG O
DROBYSKI WR
PORTER DL
GIRALT S
CHAMPLIN R
GOODMAN SA
WOLFF SN
HU W
VERFAILLIE C
LIST A
DALTON W
OGNOSKIE N
CHETRIT A
ANTIN JH
NEMUNAITIS J
Citation: Rh. Collins et al., DONOR LEUKOCYTE INFUSIONS IN 140 PATIENTS WITH RELAPSED MALIGNANCY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Journal of clinical oncology, 15(2), 1997, pp. 433-444
Authors:
NEMUNAITIS J
COX J
MEYER W
COURTNEY A
MUES G
Citation: J. Nemunaitis et al., IRINOTECAN HYDROCHLORIDE (CPT-11) RESISTANCE IDENTIFIED BY K-RAS MUTATION IN PATIENTS WITH PROGRESSIVE COLON-CANCER AFTER TREATMENT WITH 5-FLUOROURACIL (5-FU), American journal of clinical oncology, 20(5), 1997, pp. 527-529
Authors:
NEMUNAITIS J
Citation: J. Nemunaitis, A COMPARATIVE REVIEW OF COLONY-STIMULATING FACTORS, Drugs, 54(5), 1997, pp. 709-729
Authors:
ROSENFELD C
COLLINS R
PINEIRO L
AGURA E
NEMUNAITIS J
Citation: C. Rosenfeld et al., ALLOGENEIC BLOOD-CELL TRANSPLANTATION WITHOUT POSTTRANSPLANT COLONY-STIMULATING FACTORS IN PATIENTS WITH HEMATOPOIETIC NEOPLASM - A PHASE-II STUDY, Journal of clinical oncology, 14(4), 1996, pp. 1314-1319
Authors:
BROCKS DR
FREED MI
MARTIN DE
SELLERS TS
MEHDI N
CITERONE DR
BOPPANA V
LEVITT B
DAVIES BE
NEMUNAITIS J
JORKASKY DK
Citation: Dr. Brocks et al., INTERSPECIES PHARMACOKINETICS OF A NOVEL HEMATOREGULATORY PEPTIDE (SK-AND-F-107647) IN RATS, DOGS, AND ONCOLOGIC PATIENTS, Pharmaceutical research, 13(5), 1996, pp. 794-797